Business
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies. The acquired portfolio is designed to address a key limitation in neurological disease treatment, including Alzheimer's disease, where the blood-brain barrier (BBB) can restrict therapeutic
About this update from Lunai Bioworks Inc.
[{"type":"text","content":"Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications","length":160,"tagName":"p"},{"type":"text","content":"SACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies. The acquired portfolio is designed to address a key limitation in neurological disease treatment, including Alzheimer's disease, where the blood-brain barrier (BBB) can restrict therapeutic access to the brain. The expanded intellectual property portfolio introduces complementary CNS delivery technologies and multi-agent, combinatorial therapeutic approaches, which will be integrated into Lunai Bioworks IP, Inc., a wholly owned subsidiary, broadening the Company's growing platform of neurological disease and biodefense applications.","length":913,"tagName":"p"},{"type":"image","alt":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","displaySize":"","headline":null,"caption":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":123,"url":"https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q9GRWtzRx._Bb48NHqaSiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNw--/https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f","width":400,"height":123}},"href":"https://mma.prnewswire.com/media/2814530/Lunai_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The transaction integrates two distinct CNS delivery approaches into Lunai's platform: a BBB-crossing prodrug system and a nose-to-brain (N2B) delivery pathway that bypasses the BBB via olfactory and trigeminal routes. Together, these approaches are intended to support both individual and combination therapies, align with Lunai's AI-driven patient stratification strategy, expand potential applications across neurological disease, 505(b)(2) development pathways, and CNS-targeted biodefense and counter...